Status:

COMPLETED

A Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 in an Outpatient Environment

Lead Sponsor:

AbbVie

Conditions:

Parkinson's Disease (PD)

Eligibility:

All Genders

30-85 years

Phase:

PHASE1

Brief Summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of 4 weeks of continuous infusion with ABBV-951 in adult subjects with Parkinson's Disease (PD).

Eligibility Criteria

Inclusion

  • Subject with a diagnosis of definite idiopathic Parkinson's disease (PD) that is levodopa-responsive according to the United Kingdom Parkinson's Disease Society Brain Bank Criteria.
  • Subject must be taking an optimized and stable regimen of oral medications for PD, which has remained stable and unchanged for at least 30 days before enrollment in this study.
  • Subject is judged inadequately controlled on current therapy in the opinion of the Investigator and must experience a minimum of 2.5 hours of "off" time per day prior to Enrollment.
  • Subjects with a MMSE score greater than or equal to 24 and considered by the Investigator to not have dementia.

Exclusion

  • Subjects with clinically significant electrocardiogram (ECG) values.
  • History of significant skin conditions or disorders that in the Investigator's opinion would interfere with the infusion of the study drug or could interfere with study assessments.
  • Receipt of an investigational product within at least 6 weeks prior to study drug administration.
  • Subjects with moderate to severe kidney disease.
  • Consideration by the investigator for any reason that the subject is an unsuitable candidate to receive ABBV-951.
  • Patient/caregiver that cannot demonstrate proper use of the devices (drug pump and wearable device) will not be allowed to participate.

Key Trial Info

Start Date :

April 18 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 4 2019

Estimated Enrollment :

20 Patients enrolled

Trial Details

Trial ID

NCT03374917

Start Date

April 18 2018

End Date

March 4 2019

Last Update

November 12 2024

Active Locations (12)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (12 locations)

1

Banner Sun Health Res Inst /ID# 165840

Sun City, Arizona, United States, 85351

2

Loma Linda University /ID# 165592

Loma Linda, California, United States, 92354

3

Univ CA, Irvine Med Ctr /ID# 165594

Orange, California, United States, 92868

4

Compass Research /ID# 167329

Orlando, Florida, United States, 32806